Ann: Update to Interim Phase III Results for PI-88, page-23

Good post!

Bought shares today...
After this new informations this company is worth more then a day ago... IMO

Lets see when Medigen stops free falling... Limits down again... Still $1.5B marketcap....So some way to go(down)... For sure no fast tracking the drug in 2014... But coming to market not off the cards IMO...

Maybe P=0.04148 can do the trick...

Some quotations of the chairman in 2013:

Medigen designed a trial to discern whether we can reduce recurrence rates for these patients. Our 172-patient Phase II study demonstrated fantastic results in suppressing the recurrence of the so-called ‘residual’, or satellite, tumors—and I believe our Phase III study will fare even better.

In our study design, we exclusively focused on high-risk patients: those with pre-surgery tumors larger than two centimeters in diameter, and usually afflicted by a chronic viral hepatitis. Bayer did not differentiate between high-risk and low-risk groups, and as you might imagine, the recurrence rate for the latter group is already low. Medigen’s trial design is more likely to see the difference of disease free survival (DFS) between the placebo group and PI-88 treated group. Through this, Medigen is seeking to take the leading position globally in this niche.

You can enjoy success, but you should know the potential risk. Conversely, when you are down, do not be frustrated—because tomorrow is a new day.